Outclassed: The Battle for Therapeutic Market Share
Andreessen Horowitz
NOVEMBER 16, 2023
Each new modality needs to find its platform-disease fit —the diseases it is uniquely suited for. Moving forward, we expect emerging competition within Factor XI anticoagulation, hypercholesterolemia, Alpha1 antitrypsin deficiency, CD19+ tumors and autoimmunity, among many others. Source: Andreessen Horowitz research.
Let's personalize your content